Literature DB >> 25533718

The early predictive value of a decrease of metabolic tumor volume in repeated (18)F-FDG PET/CT for recurrence of locally advanced non-small cell lung cancer with concurrent radiochemotherapy.

Wei Huang1, Bo Liu2, Min Fan2, Tao Zhou3, Zheng Fu4, Zicheng Zhang3, Hongsheng Li3, Baosheng Li5.   

Abstract

PURPOSE: The aim of this study is to investigate the value of [(18)F] fluorodeoxyglucose positron emission tomography/computed tomography ((18)F FDG PET/CT) to predict recurrence of patients with locally advanced non-small cell lung cancer (NSCLC) during the early stage of concurrent chemoradiotherapy (CCRT).
METHODS: A total of 53 stage III NSCLC patients without diabetics or undergoing surgery were enrolled in the prospective study. Those patients were evaluated by FDG PET before and following 40Gy radiotherapy (RT) with a concurrent cisplatin-based heterogeneous chemotherapy regimen. Semiquantitative assessment was used to determine maximum and mean SUVs (SUVmax/SUVmean) and metabolic tumor volume (MTV) of the primary tumor. The prognostic significance of PET/CT parameters and other clinical variables was assessed using Cox regression analyses. The cutoffs of PET/CT parameters which have been determined by the previous study were used to separate the groups with Kaplan-Meier curves.
RESULTS: Recurrence rates at 1- and 2-years were 18.9% (10/53) and 50.9% (27/53) for all patients, respectively. Cox regression analysis showed that the only prognostic factor for recurrence was a decrease of MTV. Using the cutoff of 29.7%, a decrease of MTV can separate the patients into 2 groups with Kaplan-Meier curve successfully.
CONCLUSION: The prospective study has reinforced the early predictive value of MTV in repeated (18)F-FDG PET/CT for recurrence in a subgroup of locally advanced NSCLC who underwent CCRT. A decrease of MTV in (18)F-FDG uptake by the primary tumor correlates with higher LRFS.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  FDG; Non-small cell lung cancer; PET; Recurrence

Mesh:

Substances:

Year:  2014        PMID: 25533718     DOI: 10.1016/j.ejrad.2014.11.020

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  8 in total

1.  PET/CT-Based Response Evaluation in Cancer-a Systematic Review of Design Issues.

Authors:  Oke Gerke; Karen Ehlers; Edith Motschall; Poul Flemming Høilund-Carlsen; Werner Vach
Journal:  Mol Imaging Biol       Date:  2020-02       Impact factor: 3.488

2.  Regional Lymph Node Uptake of [(18)F]Fluorodeoxyglucose After Definitive Chemoradiation Therapy Predicts Local-Regional Failure of Locally Advanced Non-Small Cell Lung Cancer: Results of ACRIN 6668/RTOG 0235.

Authors:  Stephanie Markovina; Fenghai Duan; Bradley S Snyder; Barry A Siegel; Mitchell Machtay; Jeffrey D Bradley
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-11-01       Impact factor: 7.038

Review 3.  Predictive and prognostic value of tumor volume and its changes during radical radiotherapy of stage III non-small cell lung cancer : A systematic review.

Authors:  Lukas Käsmann; Maximilian Niyazi; Oliver Blanck; Christian Baues; René Baumann; Sophie Dobiasch; Chukwuka Eze; Daniel Fleischmann; Tobias Gauer; Frank A Giordano; Yvonne Goy; Jan Hausmann; Christoph Henkenberens; David Kaul; Lisa Klook; David Krug; Matthias Mäurer; Cédric M Panje; Johannes Rosenbrock; Lisa Sautter; Daniela Schmitt; Christoph Süß; Alexander H Thieme; Maike Trommer-Nestler; Sonia Ziegler; Nadja Ebert; Daniel Medenwald; Christian Ostheimer
Journal:  Strahlenther Onkol       Date:  2017-10-13       Impact factor: 3.621

4.  Effect of variations in atelectasis on tumor displacement during radiation therapy for locally advanced lung cancer.

Authors:  Nathan Tennyson; Elisabeth Weiss; William Sleeman; Mihaela Rosu; Nuzhat Jan; Geoffrey D Hugo
Journal:  Adv Radiat Oncol       Date:  2016-12-10

5.  Prognostic value of node-to-primary tumor maximum standardized uptake value ratio in T1-4N1-3M0 non-small cell lung cancer patients treated with concurrent chemo-radiotherapy.

Authors:  Tian-Cheng Li; Xin Zhao; Yi-Nuo Liu; Guo-Lin Wang; Kai-Feng Liu; Kui Zhao
Journal:  Nucl Med Commun       Date:  2022-05-13       Impact factor: 1.698

6.  Diagnosis of Lung Cancer by Fractal Analysis of Damaged DNA.

Authors:  Hamidreza Namazi; Mona Kiminezhadmalaie
Journal:  Comput Math Methods Med       Date:  2015-10-11       Impact factor: 2.238

7.  Early response evaluation using primary tumor and nodal imaging features to predict progression-free survival of locally advanced non-small cell lung cancer.

Authors:  Nasha Zhang; Rachel Liang; Michael F Gensheimer; Meiying Guo; Hui Zhu; Jinming Yu; Maximilian Diehn; Bill W Loo; Ruijiang Li; Jia Wu
Journal:  Theranostics       Date:  2020-09-23       Impact factor: 11.556

8.  Geometric and Dosimetric Changes in Tumor and Lung Tissue During Radiotherapy for Lung Cancer With Atelectasis.

Authors:  Hua Chen; Yan Shao; Xiaohua Gu; Zhijie Zheng; Hao Wang; Hengle Gu; Yanhua Duan; Aihui Feng; Ying Huang; Wutian Gan; Chongyang Chen; Zhiyong Xu
Journal:  Front Oncol       Date:  2021-07-22       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.